Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Peritoneal infection is still a frequent complication in peritoneal dialysis patients . In
France, It contributes to the technique failure, responsible for about 20% of cases of
transfer in hemodialysis. The risk of direct mortality is estimated at 1 to 6% according to
studies. Peritoneal infection is involved in the dysfunction of the peritoneal membrane.
Based on the recommendations of the International Society for Peritoneal Dialysis, the
intraperitoneal route is preferentially recommended. For many antibiotics, pharmacokinetics
(intravenous and intraperitoneal) was studied and protocols for IP administration were
validated.
Daptomycin, is a cyclic lipopeptide natural, active only on Gram-positive bacteria. It is
presented as an alternative to vancomycin in infections resistant pathogens. The stability of
daptomycin in peritoneal dialysis fluids (PDF) has been tested, and antimicrobial activity as
well.
Seven patients were treated with daptomycin intraperitoneally successfully. But no study has
reported pharmacokinetics of daptomycin via the IP route. We propose a pharmacokinetic study
of daptomycin administered intraperitoneally in 12 patients on CAPD and with Gram-positive
peritoneal infection.